About
Peptide Cancer Therapies
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyMidwest
Team (20)
Adam Yopp
PhD
MAIA Biotechnology
team_member
Charlotte Tsou
MAIA Biotechnology
team_member
Claudia A.M. Fulgenzi
MD
MAIA Biotechnology
team_member
Cristian Luput
MAIA Biotechnology
team_member
David J. Pinato
MD, MRCP (UK) FRCPath, MRes, PhD
MAIA Biotechnology
team_member
David M. Ashley
MBBS (Hon), FRACP, PhD
MAIA Biotechnology
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
527
By Phase
PHASE3: 1PHASE2: 1
By Status
NOT_YET_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06908304Lead Sponsor
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
PHASE3Not yet recruiting
300 participants
Started: Nov 3, 2025 · Completed: Jul 29, 2027
NCT05208944Lead Sponsor
THIO Sequenced With Cemiplimab in Advanced NSCLC
PHASE2Recruiting
227 participants
Started: Jun 8, 2022 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Chicago, IL, United States
Map
Loading map...